Coroner's Finding: Stocks, Michelle Jayne
Deceased
Michelle Jayne Stocks
Demographics
46y, female
Date of death
2018-12-22
Finding date
2021-05-10
Cause of death
Accidental mixed prescription drug toxicity (tramadol, amitriptyline, codeine, diazepam, alprazolam) complicating emphysema with active respiratory bronchiolitis
AI-generated summary
Michelle Jayne Stocks, aged 46, died from accidental mixed prescription drug toxicity in December 2018. She had complex medical conditions including emphysema, fibromyalgia, and chronic pain, managed by her GP Dr Q. returning from Queensland, Dr Q resumed multiple sedating medications (tramadol, amitriptyline, codeine, diazepam, alprazolam) based on a handwritten list she presented, without verifying prescribing in Queensland or conducting adequate risk assessment. Post-mortem revealed fatal tramadol and toxic levels of other CNS depressants. The coroner found Dr Q failed to undertake sufficient risk-benefit assessment, did not verify Queensland prescriptions, and over-relied on pharmacy approval rather than conducting thorough clinical due diligence. Ms Stocks' practice of hoarding medications and taking them irregularly contributed to toxicity. The coroner recommended more careful prescribing practices for complex polypharmacy regimens.
AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes.
Specialties
Error types
Drugs involved
Contributing factors
- Inadequate risk-benefit assessment of high-risk polypharmacy regimen
- Failure to verify prescriptions from Queensland treating doctors
- Reliance on unverified handwritten medication list from patient
- Over-reliance on pharmacy approval without adequate clinical due diligence
- Lack of specialist consultation for complex pain management
- Patient's practice of hoarding medications
- Patient's inconsistent medication adherence
- Patient's underlying lung disease increasing vulnerability to CNS depression
- Alcohol consumption combined with CNS depressants
Coroner's recommendations
- Dr Q should have conducted a more thorough risk-benefit assessment of the high-risk polypharmacy regimen before issuing prescriptions
- Dr Q should have independently verified prescriptions from Queensland treating doctors rather than relying on a handwritten list presented by the patient
- Dr Q should have contacted Queensland's Drugs of Dependence Unit to confirm details of any Schedule 8 medicine supplies
- Pharmacy approval should not be treated as a substitute for adequate clinical due diligence by the prescribing doctor
- Specialist consultation should have been sought for complex pain management cases
- Staged supply of medications should have been considered for high-risk regimens
- Greater caution should be exercised when treating patients after significant gaps in care or when resuming complex medication regimens without independent verification
Full text
Related cases
Source and disclaimer
This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.
Content may be incomplete, reformatted, or summarised. All court orders for redaction and non-publication are respected; documents with technically defective redaction have been excluded from the database entirely. Always refer to the original court publication for the authoritative record.
Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction —